L
Luke Whitesell
Researcher at Massachusetts Institute of Technology
Publications - 75
Citations - 8817
Luke Whitesell is an academic researcher from Massachusetts Institute of Technology. The author has contributed to research in topics: HSF1 & Drug resistance. The author has an hindex of 36, co-authored 75 publications receiving 7756 citations. Previous affiliations of Luke Whitesell include University of Arizona & University of Toronto.
Papers
More filters
Nontoxic antimicrobials that evade drug resistance
Stephen Davis,Benjamin Vincent,Matthew M. Endo,Luke Whitesell,Karen Marchillo,David R. Andes,Susan Lindquist,Martin D. Burke +7 more
TL;DR: Surprisingly, exhaustive efforts to select for mutants resistant to these more selective compounds revealed that they are just as impervious to resistance as AmB, suggesting practical routes to the discovery of less toxic, resistance-evasive therapies.
Journal ArticleDOI
Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers
Peter Tsvetkov,Ethan S. Sokol,Dexter X. Jin,Zarina Brune,Prathapan Thiru,Mahmoud Ghandi,Levi A. Garraway,Levi A. Garraway,Levi A. Garraway,Piyush Gupta,Sandro Santagata,Luke Whitesell,Susan Lindquist,Susan Lindquist +13 more
TL;DR: Analysis of data from thousands of cancer lines and tumors finds that those with suppressed expression of one or more 19S proteasome subunits show intrinsic proteasomesome inhibitor resistance, and this mechanism is associated with poor outcome in myeloma patients.
Journal ArticleDOI
Biomimetic Kinetic Resolution: Highly Enantio- and Diastereoselective Transfer Hydrogenation of Aglain Ketones To Access Flavagline Natural Products
TL;DR: A biomimetic approach for the synthesis of enantiomerically enriched aglains and rocaglamides via kinetic resolution of a bridged ketone utilizing enantioselective transfer hydrogenation is reported.
Journal ArticleDOI
HSP90: a rising star on the horizon of anticancer targets.
Chengkai Dai,Luke Whitesell +1 more
TL;DR: This review describes the discovery and development of HSP90 inhibitors as anticancer agents and their current status in the clinic, and closes with a discussion of the unique challenges confronting the further development of these agent and their prospects for the future.
Journal ArticleDOI
A Fungal-Selective Cytochrome bc1 Inhibitor Impairs Virulence and Prevents the Evolution of Drug Resistance.
Benjamin Vincent,Jean-Baptiste Langlois,Raja Srinivas,Alex K. Lancaster,Ruth Scherz-Shouval,Luke Whitesell,Bruce Tidor,Stephen L. Buchwald,Susan Lindquist +8 more
TL;DR: In this paper, a novel indazole derivative that converts azoles from fungistatic to fungicidal drugs by selective inhibition of mitochondrial cytochrome bc 1 was identified and 103 analogs were synthesized to optimize potency (half maximal inhibitory concentration 0.4μM) and fungal selectivity (28-fold over human).